Feature | November 01, 2013

Study Demonstrates Accuracy of Noninvasive CT-FFR in Evaluating CAD Patients

CT FFR, HeartFlow

HeartFlow's CT-FFR software uses supercomputing algorithms to calculate the flow of blood through a lesion in part by tracking the speed of the CT iodine contrast.

CT FFR, HeartFlow

HeartFlow's CT-FFR software showing a coronary artery tree created from a CT scan showing the FFR for a lesion.

November 1, 2013 — Clinical trial results demonstrated that a noninvasive coronary computed tomography angiography (CTA)-based test accurately assesses coronary artery disease (CAD) with results closely matching those of invasively measured fractional flow reserve (FFR), and may inform potential revascularization treatment options, including angioplasty and coronary artery bypass surgery (CABG), better than current methods. The findings of the HeartFlowNXT trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
Current guidelines for the management of stable CAD recommend non-invasive ischemia testing such as treadmill testing, single photon emission computed tomography (SPECT), stress echocardiography or cardiac magnetic resonance before invasive coronary angiography (ICA) or coronary revascularization is considered. An invasive test, FFR, is considered the gold standard for lesion-specific coronary revascularization decisions in patients with stable CAD. 
 
However, the current noninvasive testing options such as treadmill testing, SPECT and stress echocardiography correlate poorly to FFR, and thus selection of patients for invasive angiography and coronary revascularization is often inaccurate.
 
The HeartFlowNXT trial was a blinded, prospective core lab adjudicated trial that investigated FFR-CT, a new, noninvasive FFR calculation derived from CTA images and using high-performance computing to create a 3-D map of the coronary arteries showing locations of obstructions and FFR-CT values.
 
The primary study objective was to compare per-patient diagnostic performance of FFR-CT compared to coronary CTA alone for the diagnosis of at least one hemodynamically significant stenosis using direct measurement of FFR (? 0.8) as the reference standard. The trial also measured per-vessel and per-patient diagnostic accuracy, sensitivity and specificity as well as positive and negative predictive values of FFR-CT.
 
The prospective study enrolled 254 patients scheduled to undergo non-emergent clinically indicated invasive angiography due to suspected CAD. 
 
The FFR-CT data matched closely with invasively measured FFR. The area under the receiver operating characteristic curve (AUC) for FFR-CT (? 0.8) was 0.82 versus 0.63 for coronary CTA (p < 0.0001) with invasive FFR as the reference standard. Per-patient sensitivity and specificity were 86 percent and 79 percent for FFR-CT versus 94 percent and 34 percent for coronary CTA and 91 percent and 51 percent for invasive coronary angiography (lumen reduction > 50 percent).
 
“Fractional flow reserve non-invasively calculated from coronary CTA data sets matches closely with invasively measured FFR and allows for identification of patients with hemodynamically significant coronary lesions with good accuracy. When compared to both coronary CTA and ICA, FFR-CT led to a significant reduction in the proportion of false-positive results,” said Bjarne Nørgaard, M.D., Ph.D., Aarhaus University Hospital, Denmark and lead investigator of the study. “The addition of FFR-CT to coronary CTA allows for a comprehensive anatomic and functional assessment of coronary artery disease.”
 

Limits of the Current Technology

CT-FFR may one day eliminate the need to refer patients for diagnostic catheter angiographies. However, today, users of the HeartFlow technology say it requires sending the CT DICOM dataset to the company in California. It then takes the supercomputing power of the HeartFlow computer system about a day to process the data and render a report. While this may eliminate CT-FFR's use for acute chest pain patients, it offers an option for patients considering elective PCI. Coronary CT experts say computing speed and power doubles every couple years, which will eventually enable CT-FFR to be processed onsite in minutes, instead of days or hours. 

For more information: www.crf.org

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Hitachi Supria True64 CT Receives FDA Clearance
Technology | Computed Tomography (CT)| September 15, 2017
Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init